Q-omics provides the consensus-scored GOLGA6B profile across patient tissues and cancer cell-line models. GOLGA6B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GOLGA6B is differentially expressed in 6, with the highest sampling consensus in CHOL. Additionally, GOLGA6B RNA expression shows 11,994 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and CHOL as cancer lineages where GOLGA6B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA6B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA6B survival associations across molecular data types. GOLGA6B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA6B RNA expression–survival associations across cancer types. High GOLGA6B expression shows unfavorable associations in UVM, UCS, THCA, READ, LUAD and KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for GOLGA6B RNA expression.
This table summarizes GOLGA6B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA6B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA6B shows lower tumor expression in CHOL, LIHC and THCA and higher tumor expression in KIRP, HNSC and LUSC. The CHOL box plot shows higher GOLGA6B RNA expression in normal versus tumor tissue (log2 FC = −0.227, t-test p = .001).
This table shows molecular features associated with GOLGA6B in patient tissues and cancer cell lines. In patient samples, GOLGA6B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA6B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SKIN.
